Clinical trial NCT02014545: Evaluation of Lucanthone to Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer
Official title: Phase II Trial Evaluating the Addition of Lucanthone to Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Brain Metastases
Non-small Cell Lung Cancer
Keywords: brain metastases
non-small cell lung cancer
whole brain radiation therapy
lucanthone
Lead sponsor: Wake Forest University Health Sciences
Sponsor class: OTHER
Collaborators: name: Spectrum Pharmaceuticals, Inc
First posted: 2013-12-18
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a randomized, double blind placebo controlled study to evaluate safety and efficacy of lucanthone administered as an adjunct to patients receiving whole brain radiation therapy (WBRT) as primary treatment for brain metastases secondary to non-small cell lung cancer.

Detailed description: Eligible patients for this trial will be randomized to lucanthone or placebo in a ratio of 1:1. The treatment will consist of WBRT given in a dose of 30 Gy in ten fractions. Lucanthone/placebo will be given as an adjunct to the WBRT on days that WBRT is administered. Tumor assessments will be done with a brain MRI. Radiological assessments on the tumor will be made periodically throughout the study and will be discontinued at the time of tumor progression. Safety will be evaluated for one year during the study period and survival data will be collected thereafter.

Eligibility criteria: Inclusion Criteria:

* The patient has given informed consent.
* The patient is willing and able to abide by the protocol.
* The patient is between age 18 and 70 (between 19 and 70 in Alabama).
* The patient has histologically proven NSCLC with radiologically documented brain metastases.
* Newly diagnosed or stable systemic disease, on or off systemic therapy.
* If receiving systemic therapy for NSCLC, at least two weeks since patient received systemic therapy.
* Able to withhold systemic therapy for duration of WBRT therapy.
* If the patient is of childbearing potential, he/she is using an acceptable/effective method of contraception.
* The patient's Karnofsky Score is greater than or equal to 70%.

Exclusion Criteria:

* Patient has a diagnosis of recurrent brain metastases.
* The patient has an absolute neutrophil count less than or equal to 1.5 X 10 9/L.
* The patient has a screening platelet count less than 100,000/uL.
* The patient has a screening bilirubin greater than 1.6 mg/dL.
* The patient has a screening creatinine greater than 2.25 mg/dL in men and 1.8 mg/dL in women.
* The patient has a screening ALT/AST greater than 2.5 times the upper limit of the laboratory reference range.
* The patient has an unstable medical condition or significant comorbid pathophysiology (e.g. active infection, poorly controlled diabetes, unstable angina, severe heart failure) that would interfere with his/her participation in the study.
* The patient is enrolled, or plans to enroll, in a concurrent treatment protocol with another investigational product.
* The patient has received prior chemotherapy or radiation therapy within two weeks of beginning WBRT on protocol.
* The patient is allergic to gadolinium contrast.
* More than 21 days has or will elapse between the brain MRI documenting the brain metastases and the initiation of WBRT.

Primary outcomes:
measure: Determine the efficacy of lucanthone when given during WBRT
timeFrame: 2 weeks to 13 months
Secondary outcomes:
measure: Evaluate the safety and toxicity of lucanthone when used in combination with standard doses of WBRT in the primary treatment of brain metastases secondary to non-small cell lung cancer
timeFrame: 2 weeks to 13 months
Other outcomes:
Locations:
city: Winston-Salem
country: United States
facility: Comprehensive Cancer Center of Wake Forest University
state: North Carolina
Study officials:
affiliation: Wake Forest University Health Sciences
name: Stefan C. Grant, MD, JD
role: PRINCIPAL_INVESTIGATOR
References: